免疫检查点抑制剂 英语是什么意思 - 英语翻译

• immune checkpoint inhibitors
• immune checkpoint inhibitor

在 中文 中使用 免疫检查点抑制剂 的示例及其翻译为 英语

免疫检查点抑制剂已被批准用于其他类型的癌症，如黑素瘤和肺癌，但目前不适用于胰腺癌。
Immune checkpoint inhibitors are already approved for other types of cancer, like melanoma and lung cancer, but not for pancreatic cancer.

数种免疫检查点抑制剂已获得全球各国监管机构批准。
A few immune checkpoint inhibitors have been approved by regulatory authorities around the world.

Opdivo是一种PD-1免疫检查点抑制剂，旨在克服免疫抑制。
Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression.

现有的癌症免疫疗法主要运用免疫检查点抑制剂*2，但仅对小部分患者有效。
At present, cancer immunotherapies that use immune checkpoint inhibitors** are being performed, however, it is effective only in a small group of patients.

这一战略合作使我们能够在多个注册试验中快速开发NKTR-214与获批PD-1免疫检查点抑制剂组合。
This strategic collaboration allows us to very quickly develop NKTR-214 with the leading approved PD-1 immune checkpoint inhibitor in numerous registrational trials.”.

到目前为止，免疫检查点抑制剂约在五分之一的NSCLC患者中有很好的疗效。
So far, immune checkpoint inhibitors have received a positive response among about one in five patients with NSCLC.

Ipilimumab靶向作用于T细胞表面上的CTLA-4检查点，是首个免疫检查点抑制剂。
Ipilimumab targets the CTLA-4 checkpoint on T cells and was the first immune checkpoint inhibitor.

免疫检查点抑制剂在几种类型的癌症中展示出显著的临床益处，从而导致它们在临床实践中获得广泛应用。
Immune checkpoint inhibitors showed significant clinical benefits for several types of cancers, leading to their wide application in clinical practice.

免疫检查点抑制剂，如抗pd-1抗体pembrolizumab，已经成为治疗非小细胞肺癌的重要工具。
Immune checkpoint inhibitors, such as the anti-PD-1 antibody pembrolizumab, have become important tools for managing non-small-cell lung cancer.

如今，免疫治疗可谓是肿瘤界的宠儿，尤其是免疫检查点抑制剂（ICIs）可能是最有前景的免疫治疗。
Immunotherapy is a hot spot in the field of tumor therapy, especially immune checkpoint inhibitors(ICIs) may be the most promising immunotherapy.

免疫检查点抑制剂在几种类型的癌症中展示出显著的临床益处，从而导致它们在临床实践中获得广泛应用。
Immune checkpoint inhibitors show significant clinical benefit in several types of cancers, leading to their wide application in clinical practice.

癌症免疫疗法包括广泛的药物和治疗方法，包括疫苗、免疫检查点抑制剂，以及最近的细胞疗法。
Cancer immunotherapy encompasses a broad range of medicines and treatment approaches, including vaccines, immune checkpoint inhibitors, and, most recently, cellular therapies.

此外，一些免疫治疗方法，如CART细胞和免疫检查点抑制剂，受T细胞寿命的限制。
In addition, some immunotherapy treatments, such as CAR T cells and immune checkpoint inhibitors, are limited by the life span of T cells.

Y-诱捕器还可以提供针对能抵抗当前免疫检查点抑制剂的肿瘤的治疗策略。
Y-traps could also provide a therapeutic strategy against tumors that resist current immune checkpoint inhibitors.”.

此外，血液测试可能测量治疗的有效性，比如外泌体中的PD-L1水平可能指示免疫检查点抑制剂对T细胞的活化水平。
Furthermore, blood analysis can measure the effectiveness of the treatment, e.g., levels exosomal PD-L1 may indicate the level of T-cell activation inhibitors immune checkpoint.

此外，血液测试可以测量治疗的有效性，例如，外体PD-L1水平可以指示免疫检查点抑制剂对T细胞的激活水平。
Furthermore, blood analysis can measure the effectiveness of the treatment, e.g., levels exosomal PD-L1 may indicate the level of T-cell activation inhibitors immune checkpoint.

如果确实如此，肿瘤可能与免疫检查点抑制剂治疗诸如pembrolizumab（Keytruda®）。
If it does, the tumor may be treated with an immune checkpoint inhibitor such as pembrolizumab(Keytruda®).

年8月1日，免疫检查点抑制剂首次获得批准的适应证仅两种，即黑色素瘤和肺癌。
On Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer- melanoma and lung cancer.

已经通过组合免疫检查点抑制剂nivolumab和ipilimumab（Yervoy）尝试了这种方法。
This has been attempted by combining the immune checkpoint inhibitors nivolumab and ipilimumab(Yervoy).

她总结道：“免疫检查点抑制剂已开始改变膀胱癌的治疗前景。
She concluded:"Immune check point inhibitors have started to alter the therapeutic landscape for bladder cancer.

到目前为止，免疫检查点抑制剂约在五分之一的NSCLC患者中有很好的疗效。
To date, immune checkpoint blockers work well for about one-fifth of NSCLC patients.

这两种药物均为免疫检查点抑制剂，它们对某些癌细胞释放一种强有力的免疫系统攻击。
Both drugs are immune checkpoint inhibitors that unleash a potent immune system attack on certain cancer cells.

Choueiri说cabozantinib也正在研究作为潜在的一线治疗，并在早期试验结合cabozantinib免疫检查点抑制剂。
Choueiri said cabozantinib is also being studied as a potential first-line treatment and is in early trials combining cabozantinib with immune checkpoint inhibitors.

当前科研的一个主要焦点是在特异患者群体中找到免疫检查点抑制剂和其它药物的最佳组合。
A major focus of current research is identifying which combinations of immune checkpoint inhibitors and other drugs work best in specific patients.

由于DUX4在许多癌症中表达，因此阻断其活性可能会增加免疫检查点抑制剂的成功。
Because DUX4 is expressed in many cancers, blocking its activity might increase the success of immune checkpoint inhibitors.

Gobert及其同事评估了法国国家CANCERVIH数据库中470名患者使用免疫检查点抑制剂nivolumab（Opdivo）的疗效和耐受性。
Gobert and colleagues assessed the efficacy and tolerability of the immune checkpoint inhibitor nivolumab(Opdivo) among 470 people in the French national CANCERVIH database.

PD-L1测试可帮助医生确定患者是否可能从被称为免疫检查点抑制剂的癌症药物中获益。
A PD-L1 test helps doctors determine whether a patient is likely to benefit from cancer drugs known as immune checkpoint inhibitors.

总体来说，1级毒性可以在密切监测下继续使用免疫检查点抑制剂，除某些神经、血液和心脏毒性。
In general, immune checkpoint inhibitor therapy should be continued with close monitoring for grade 1 toxicities, with the exception of some neurologic, hematologic, and cardiac toxicities.

卡瑞利珠单抗（Camrelizumab，研发代号SHR-1210，商品名艾瑞卡）（INN[1]）是一种抗PD-1免疫检查点抑制剂，正在针对肝细胞癌的适应症进行多国临床试验。[2].
Camrelizumab(SHR-1210)(INN[1]) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma.[2].